AU Patent

AU2023275457A1 — Gene therapy compositions and methods of use thereof

Assigned to AstraZeneca AB · Expires 2024-11-28 · 1y expired

What this patent protects

Presented herein are compositions and methods for gene therapy.

USPTO Abstract

Presented herein are compositions and methods for gene therapy.

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: AU2023275457A1
Jurisdiction: AU
Classification: —
Expires: 2024-11-28
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.